Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Hyundai Motor (005380) – Reference Price for Ex-Interim (Quarterly) Dividend (Hyundai Motor 2nd Preferred B) / 2025-11-26 Disclosures
  • [Disclosure] SK Square (402340) – Decision on Cancellation of Shares / 2026-03-25 Semiconductors
  • [Disclosure] Celltrion (068270) – Execution of Platform Technology License Agreement with TRiOar / 2025-11-19 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Announcement / 2025-07-18 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Results of Annual General Meeting of Shareholders / 2024-03-26 Disclosures
  • [Disclosure] Samsung Biologics (207940) – Submission of Audit Report / 2025-02-25 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Holding (Notice) / 2024-10-17 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Results of Annual General Meeting of Shareholders / 2025-03-20 Disclosures

Category: Disclosures

[Disclosure] Celltrion (068270) – (Correction) Provisional Consolidated Financial Results / 2026-07-27

Posted on July 27, 2026August 5, 2026 By K-STOCK Editor
[Disclosure] Celltrion (068270) – (Correction) Provisional Consolidated Financial Results / 2026-07-27

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has issued a correction to its Q2 2026 provisional financial results. Compared to the initial disclosure, the Q2 consolidated revenue has been revised upward to KRW 1.3937T and operating profit to KRW 451.8B. 📊 [Summary of Key Disclosure Content & Major Figures] [Corrections in Q2…

Read More “[Disclosure] Celltrion (068270) – (Correction) Provisional Consolidated Financial Results / 2026-07-27” »

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Aerospace (012450) – Major Management Matters Related to Investment Decisions / 2026-07-27

Posted on July 27, 2026August 9, 2026 By K-STOCK Editor
[Disclosure] Hanwha Aerospace (012450) – Major Management Matters Related to Investment Decisions / 2026-07-27

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Aerospace executed a master goods supply agreement exceeding 2.5% of its annual revenue, but deferred disclosure of detailed terms (contract value, counterparty, etc.) due to confidentiality obligations requested by the counterparty. 📊 [Key Disclosure Contents & Major Figures Summary] [Disclosure Deferral & Other Information] 📝…

Read More “[Disclosure] Hanwha Aerospace (012450) – Major Management Matters Related to Investment Decisions / 2026-07-27” »

Disclosures, Defense

[Disclosure] Hanwha Ocean (042660) – Provisional Performance (Consolidated Financial Results) / 2026-07-27

Posted on July 27, 2026August 8, 2026 By K-STOCK Editor
[Disclosure] Hanwha Ocean (042660) – Provisional Performance (Consolidated Financial Results) / 2026-07-27

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Ocean reported its provisional Q2 2026 consolidated financial results, recording revenue of KRW 5.44T (+65.2% YoY) and operating profit of KRW 736.1B (+98.0% YoY), reflecting year-on-year increases across key metrics. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying…

Read More “[Disclosure] Hanwha Ocean (042660) – Provisional Performance (Consolidated Financial Results) / 2026-07-27” »

Disclosures, Shipbuilding

[Disclosure] Hanwha Ocean (042660) – Operational Status of Compliance Program (Informational Disclosure) / 2026-07-27

Posted on July 27, 2026August 8, 2026 By K-STOCK Editor
[Disclosure] Hanwha Ocean (042660) – Operational Status of Compliance Program (Informational Disclosure) / 2026-07-27

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Ocean reported to its Board of Directors on July 27, 2026, and disclosed the 1H 2026 operational performance and 2H 2026 plans for its Fair Trade Compliance Program (CP). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring 2H…

Read More “[Disclosure] Hanwha Ocean (042660) – Operational Status of Compliance Program (Informational Disclosure) / 2026-07-27” »

Disclosures, Shipbuilding

[Disclosure] SK hynix (000660 / SKHY) – Additional Listing (Capital Increase (DR)) / 2026-07-24

Posted on July 24, 2026August 11, 2026 By K-STOCK Editor
[Disclosure] SK hynix (000660 / SKHY) – Additional Listing (Capital Increase (DR)) / 2026-07-24

Fact Source: Financial Supervisory Service DARTMarket: KOSPI (000660) 💡 3-Second Summary 17,790,000 newly issued common shares of SK Hynix, issued through a capital increase via Depositary Receipts (DR), will be additionally listed on the domestic stock market. 📊 [Key Summary & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Changes in Total Issued…

Read More “[Disclosure] SK hynix (000660 / SKHY) – Additional Listing (Capital Increase (DR)) / 2026-07-24” »

Disclosures, Semiconductors

[Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) Europe Marketing Authorization Application / 2026-07-24

Posted on July 24, 2026August 5, 2026 By K-STOCK Editor
[Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) Europe Marketing Authorization Application / 2026-07-24

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) and the European Commission (EC) for CT-P55, a biosimilar to Cosentyx (a treatment for autoimmune diseases). Based on the clinical data obtained, the company is seeking approval for all full adult and pediatric…

Read More “[Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) Europe Marketing Authorization Application / 2026-07-24” »

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Europe Phase 3 Clinical Trial Plan Application (Part 1 & 2) (Rheumatoid Arthritis Patients) / 2026-07-24

Posted on July 24, 2026August 5, 2026 By K-STOCK Editor
[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Europe Phase 3 Clinical Trial Plan Application (Part 1 & 2) (Rheumatoid Arthritis Patients) / 2026-07-24

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application for Part 1 & Part 2 of a Phase 3 clinical trial plan to the European Medicines Agency (EMA) for Zymfentra (CT-P13 SC) in patients with rheumatoid arthritis. The study aims to secure additional clinical data, including racial diversity and varied…

Read More “[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Europe Phase 3 Clinical Trial Plan Application (Part 1 & 2) (Rheumatoid Arthritis Patients) / 2026-07-24” »

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) U.S. Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24

Posted on July 24, 2026August 5, 2026 By K-STOCK Editor
[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) U.S. Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application to the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial plan for Zymfentra (CT-P13 SC) in patients with rheumatoid arthritis. The trial aims to secure additional clinical data, including patient racial diversity and varied treatment histories. 📊…

Read More “[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) U.S. Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24” »

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Korea Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24

Posted on July 24, 2026August 5, 2026 By K-STOCK Editor
[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Korea Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an application to the Ministry of Food and Drug Safety (MFDS) for a Phase 3 clinical trial plan in South Korea for Zymfentra (CT-P13 SC) in patients with rheumatoid arthritis. The study aims to secure additional clinical data, including patient demographics and prior…

Read More “[Disclosure] Celltrion (068270) – CT-P13 SC (Zymfentra) Korea Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients) / 2026-07-24” »

Disclosures, Bio & Healthcare

[Disclosure] Hyundai Motor (005380) – Suspension of Production / 2026-07-24

Posted on July 24, 2026August 11, 2026 By K-STOCK Editor
[Disclosure] Hyundai Motor (005380) – Suspension of Production / 2026-07-24

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hyundai Motor Company has decided to temporarily suspend automobile manufacturing operations at its Asan Plant from July 25 to August 11, 2026, for aging equipment replacement work. The revenue of the suspended sector is approximately KRW 9.56T, representing 5.13% of recent consolidated annual revenue. 📊 [Key…

Read More “[Disclosure] Hyundai Motor (005380) – Suspension of Production / 2026-07-24” »

Disclosures, Automotive

Posts pagination

Previous 1 … 3 4 5 … 252 Next
  • [Disclosure] Hyundai Motor (005380) – Clarification on Rumors or News Reports (Unconfirmed) / 2024-02-07 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Single Sales/Supply Contract / 2024-04-17 Disclosures
  • [Disclosure] Celltrion (068270) – Decision on Acquisition of Shares and Equity Securities of Other Corporation (Correction) / 2025-12-11 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Results of Annual General Meeting of Shareholders / 2025-03-20 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | Tight MLCC Supply & Non-IT Overtaking IT · Multi-Client AI FC-BGA · Target Price Upgrade / 2025-09-03 RESEARCH
  • [Disclosure] Daeduck Electronics (353200) – Submission of Audit Report / 2025-03-17 Semiconductors
  • [Research] SK hynix (000660 / SKHY) – Shinhan | HBM Demand · Cost Competitiveness · Earnings Growth / 2025-09-30 RESEARCH
  • [Disclosure] Wonik IPS (240810) – Decision on Disposal of Treasury Shares / 2023-11-30 Semiconductors

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme